Imagin500 mg

Imagin is indicated for the management of type 2 diabetes mellitus (T2DM) in adults, used to improve glycemic control alongside diet and exercise.

• Guideline/approved use: As monotherapy in patients with type 2 diabetes who have inadequate glycemic control on diet and exercise alone, particularly where metformin is not tolerated or is contraindicated.
• Combination use: As an add-on to other oral antidiabetic agents (such as metformin, sulfonylureas, or DPP-4 inhibitors) or to insulin, when monotherapy does not achieve adequate glycemic control.

Imagin belongs to a relatively new therapeutic class, and its place in overall diabetes treatment algorithms is still evolving as more clinical experience accumulates. It is not indicated for type 1 diabetes or diabetic ketoacidosis.

Each tablet contains Imeglimin Hydrochloride as the active ingredient, typically formulated as 500 mg or 1000 mg strength tablets (equivalent imeglimin base content may vary by manufacturer). Please refer to the specific product label for exact strength.

Imagin is an oral antidiabetic medicine belonging to a novel drug class sometimes referred to as "glimins." It is structurally related to metformin (a biguanide-type structure) but has a distinct mechanism centered on improving mitochondrial bioenergetics in multiple tissues involved in glucose regulation.

Unlike older antidiabetic classes such as sulfonylureas, DPP-4 inhibitors, or SGLT2 inhibitors, Imagin works through a triple mechanism affecting the pancreas, liver, and skeletal muscle simultaneously. As a comparatively newer medicine, real-world long-term safety and outcomes data are still accumulating, and it should be used with appropriately current clinical guidance.

Imagin belongs to the "glimin" class of oral antidiabetic agents — a novel, structurally distinct class related to but separate from biguanides, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and thiazolidinediones.

Imeglimin Hydrochloride acts through a unique, tetrahydrotriazine-based structure that modulates mitochondrial bioenergetics. Its proposed triple mechanism of action includes:

• Pancreas: Restoration of glucose-stimulated insulin secretion from beta cells.
• Liver: Inhibition of hepatic gluconeogenesis, reducing excess glucose production.
• Skeletal muscle: Enhancement of glucose uptake, improving peripheral insulin sensitivity.

These effects are thought to occur via modulation of the mitochondrial respiratory chain, an action mechanistically related to (though distinct from) metformin. Because of this shared mitochondrial mechanism, precautions relevant to biguanides (such as risk in hypoxic or hepatic/renal impairment states) are applied conservatively to Imeglimin Hydrochloride as well.

Imagin tablets should be swallowed whole with a glass of water, morning and evening, at approximately the same times each day. It may be taken with or without food. Do not crush or chew the tablet unless directed by a physician. If a dose is missed, it should be taken as soon as remembered unless it is close to the next scheduled dose — do not double the dose.

Imagin has the following clinically significant interactions:

• Insulin and insulin secretagogues (e.g., sulfonylureas): Concurrent use increases the risk of hypoglycemia; dose adjustment of the concomitant agent may be needed.
• Alcohol: Excessive alcohol intake may increase the risk of lactic acidosis, given the drug's mitochondrial mechanism related to biguanides; patients should be advised to avoid excessive alcohol use.
• Iodinated contrast media: As a conservative precaution similar to metformin, temporary discontinuation may be advised by the physician around procedures using iodinated contrast, particularly in patients with reduced renal function.
• Other nephrotoxic or hepatotoxic drugs: Caution is advised when co-administered, as impaired renal or hepatic clearance may increase systemic exposure.

Reported adverse effects with Imagin include:

• Gastrointestinal: Nausea, diarrhea, constipation, and abdominal discomfort are the most commonly reported effects.
• Hypoglycemia: Primarily when used in combination with insulin or sulfonylureas.
• Rare/theoretical: Lactic acidosis — a rare but serious risk considered on the basis of the drug's mitochondrial mechanism shared with biguanides, particularly in patients with predisposing conditions (see Precautions and Warnings).

Patients should report persistent gastrointestinal symptoms, unusual muscle pain, breathing difficulty, or unexplained fatigue promptly to their physician.

Imagin should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus, as adequate human safety data are not available for this comparatively new medicine. Insulin is generally preferred for glycemic control during pregnancy. It is not known whether Imagin passes into breast milk; a decision to continue or discontinue breastfeeding, or to continue or discontinue therapy, should be made in consultation with a physician, taking into account the benefit of the drug to the mother.

• Limited long-term safety data: Imagin belongs to a relatively new drug class; long-term real-world safety experience is more limited compared to established antidiabetic agents. Use should be guided by current clinical evidence and physician judgment.
• Lactic acidosis risk: Because of structural and mechanistic similarity to biguanides, Imagin should be used with caution and conservatively avoided in conditions predisposing to lactic acidosis, including renal impairment, hepatic impairment, hypoxic conditions (e.g., severe cardiac or respiratory failure, sepsis, dehydration), and excessive alcohol intake.
• Renal function monitoring: Periodic assessment of renal function is recommended during treatment.
• Hypoglycemia: Increased risk when combined with insulin or insulin secretagogues; patients should be counselled on recognizing and managing hypoglycemia.
• Surgery/acute illness: Consider temporary discontinuation during major surgery, acute serious illness, or conditions causing tissue hypoxia, as advised by the physician.

In case of suspected overdose of Imagin, the main concern is an increased risk of hypoglycemia and, theoretically, lactic acidosis. Seek immediate medical attention or contact emergency services/poison control. Supportive care and monitoring of blood glucose and metabolic status should be provided by a healthcare facility; there is no specific antidote. Do not attempt home treatment of a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: Contraindicated in severe renal impairment; use with caution and physician oversight in mild-to-moderate impairment (see Contraindications and Dosage).
• Hepatic impairment: Limited data; use with caution and close monitoring.
• Elderly: Use with caution, considering age-related decline in renal function; start at the lower end of dosing range with monitoring.
• Pediatric patients: Safety and efficacy of Imagin have not been established in children and adolescents; not recommended for use in this population.
• Pregnancy and lactation: See Pregnancy and Lactation section.

Imagin is generally used as a long-term, ongoing treatment for chronic management of type 2 diabetes, similar to other oral antidiabetic agents. Duration of therapy should be determined by the treating physician based on glycemic control, tolerability, and periodic reassessment (including renal function monitoring).

Imeglimin Hydrochloride belongs to the "glimin" class of oral antidiabetics — a novel class structurally related to biguanides (metformin) but pharmacologically and chemically distinct.

Imeglimin Hydrochloride modulates mitochondrial bioenergetics to produce a triple therapeutic effect: it restores glucose-stimulated insulin secretion in the pancreas, inhibits excessive glucose production (gluconeogenesis) in the liver, and enhances glucose uptake in skeletal muscle — together improving overall glycemic control in type 2 diabetes.

The safety and efficacy of Imagin have not been established in pediatric patients. It is therefore not recommended for use in children or adolescents outside of specialized clinical settings, until further data become available.